Drugs / MB310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06582264 | Sep 2024 → Jan 2026 | ulcerative colitis | Microbiotica Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-02-11 | Microbiotica Ltd | Results Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis microbiotica.com ↗
Clinical remission achieved in 63.2% (12/19) MB310 treated patients vs 30.0% (3/10) in placebo treated patients (ITT analysis) |
| 2025-05-06 | Microbiotica Ltd | Results Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier microbiotica.com ↗
Data from new preclinical studies presented at DDW demonstrated that three bacterial strains in MB310 enhance the epithelial barrier integrity by three distinct mechanisms: release of nicotinic acid; polyamine production; and expression of a novel protein IZOR (Internalin-like ZO1 Regulator). |
| 2025-02-21 | Microbiotica Ltd | Results Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis microbiotica.com ↗
This included novel data demonstrating that different strains induce regulatory T-cells by different mechanisms. |
| 2024-08-27 | Microbiotica Ltd | Regulatory Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies microbiotica.com ↗
Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce that it has received regulatory approvals to initiate clinical studies for its first two programmes in advanced melanoma (MELODY-1) and ulcerative colitis (COMPOSER-1) in selected EU countries and the UK. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06582264 ↗ |
| Modality | Other / unclassified | “Live bacterial therapeutic for oral administration” NCT06582264 ↗ |
| Route | Oral | “Live bacterial therapeutic for oral administration” NCT06582264 ↗ |